[go: up one dir, main page]

WO2004089291A3 - Tumor-targeting drug-loaded particles - Google Patents

Tumor-targeting drug-loaded particles Download PDF

Info

Publication number
WO2004089291A3
WO2004089291A3 PCT/US2004/010230 US2004010230W WO2004089291A3 WO 2004089291 A3 WO2004089291 A3 WO 2004089291A3 US 2004010230 W US2004010230 W US 2004010230W WO 2004089291 A3 WO2004089291 A3 WO 2004089291A3
Authority
WO
WIPO (PCT)
Prior art keywords
microparticles
tumor
nanoparticles
therapeutic agent
tumors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/010230
Other languages
French (fr)
Other versions
WO2004089291A2 (en
Inventor
Jessie L-S Au
M Guillaume Wientjes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to AU2004228008A priority Critical patent/AU2004228008B2/en
Priority to JP2006509638A priority patent/JP4927535B2/en
Priority to EP04758803A priority patent/EP1608359A4/en
Priority to CN2004800156847A priority patent/CN1816331B/en
Priority to CA2520475A priority patent/CA2520475C/en
Publication of WO2004089291A2 publication Critical patent/WO2004089291A2/en
Publication of WO2004089291A3 publication Critical patent/WO2004089291A3/en
Priority to IL171185A priority patent/IL171185A/en
Priority to US11/242,546 priority patent/US8043631B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epoxy Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

A composition for delivering a tumor therapeutic agent to a patient includes a fast-release formulation of a tumor apoptosis inducing agent, a slow-release formulation of a tumor therapeutic agent, and a pharmaceutically acceptable carrier. An apoptosis-inducing agent in a pharmaceutically acceptable carrier may be administered before or concomitantly therewith. Nanoparticles or microparticles (e.g., cross-linked gelatin) of the therapeutic agent (e.g., paclitaxel) also may be used. The nanoparticles or microparticles may be coated with a bioadhesive coating. Microspheres that agglomerate to block the entrance of the lymphatic ducts of the bladder to retard clearance of the microparticles through the lymphatic system also may be employed. This invention also uses drug-loaded gelatin and poly(lactide-co-glycolide) (PLGA) nanoparticles and microparticles to target drug delivery to tumors in the peritoneal cavity, bladder tissues, and kidneys. Fig. 1 (left) shows multiple tumors disseminated through the peritoneal cavity of a mouse implanted with intraperitoneal human Hs766T pancreatic xenograft tumors under room light and (right) under UV light.
PCT/US2004/010230 2003-04-03 2004-04-02 Tumor-targeting drug-loaded particles Ceased WO2004089291A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU2004228008A AU2004228008B2 (en) 2003-04-03 2004-04-02 Tumor-targeting drug-loaded particles
JP2006509638A JP4927535B2 (en) 2003-04-03 2004-04-02 Particles encapsulating drugs that target tumors
EP04758803A EP1608359A4 (en) 2003-04-03 2004-04-02 Tumor-targeting drug-loaded particles
CN2004800156847A CN1816331B (en) 2003-04-03 2004-04-02 Particles loaded with tumor targeting drugs
CA2520475A CA2520475C (en) 2003-04-03 2004-04-02 Tumor-targeting drug-loaded particles
IL171185A IL171185A (en) 2003-04-03 2005-09-29 Tumor-targeting drug-loaded particles
US11/242,546 US8043631B2 (en) 2004-04-02 2005-10-03 Tumor targeting drug-loaded particles

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46082703P 2003-04-03 2003-04-03
US60/460,827 2003-04-03

Publications (2)

Publication Number Publication Date
WO2004089291A2 WO2004089291A2 (en) 2004-10-21
WO2004089291A3 true WO2004089291A3 (en) 2005-04-21

Family

ID=33159807

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/010230 Ceased WO2004089291A2 (en) 2003-04-03 2004-04-02 Tumor-targeting drug-loaded particles

Country Status (8)

Country Link
EP (1) EP1608359A4 (en)
JP (1) JP4927535B2 (en)
KR (1) KR100849911B1 (en)
CN (2) CN1816331B (en)
AU (1) AU2004228008B2 (en)
CA (1) CA2520475C (en)
IL (1) IL171185A (en)
WO (1) WO2004089291A2 (en)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005084710A2 (en) * 2004-03-02 2005-09-15 Massachusetts Institute Of Technology Nanocell drug delivery system
RU2404747C2 (en) * 2005-03-31 2010-11-27 Лиддс Аб Method for treatment of prostate gland diseases based on local delivery of active materials
BRPI0600285C1 (en) * 2006-01-13 2011-10-11 Brz Biotecnologia Ltda nanoparticulate pharmaceutical compounds useful for treating restenosis
JP2007277217A (en) * 2006-03-17 2007-10-25 Fujifilm Corp Biodegradable matrix encapsulating drug uniformly
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
EP2086602A2 (en) * 2006-11-20 2009-08-12 Lutonix, Inc. Drug releasing coatings for medical devices
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
EP2074988B1 (en) 2007-12-28 2018-03-14 Industrial Technology Research Institute Sustained release composition and manufacturing method thereof
US9161943B2 (en) 2007-12-31 2015-10-20 Industrial Technology Research Institute Sustained release composition and manufacturing method thereof
WO2009116556A1 (en) * 2008-03-19 2009-09-24 富士フイルム株式会社 Pharmaceutical composition for injection
JP2012501966A (en) 2008-06-16 2012-01-26 バインド バイオサイエンシズ インコーポレイテッド Vinca alkaloid-containing therapeutic polymer nanoparticles and methods for making and using the same
US8613951B2 (en) 2008-06-16 2013-12-24 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same
EP2309990B2 (en) 2008-06-16 2017-03-15 Pfizer Inc. Drug loaded polymeric nanoparticles and methods of making and using same
WO2010068866A2 (en) 2008-12-12 2010-06-17 Bind Biosciences Therapeutic particles suitable for parenteral administration and methods of making and using same
EP2379064B1 (en) 2008-12-15 2020-02-26 Pfizer Inc. Long circulating nanoparticles for sustained release of therapeutic agents
DK2509634T3 (en) 2009-12-11 2019-04-23 Pfizer Stable formulations for lyophilization of therapeutic particles
US9295649B2 (en) 2009-12-15 2016-03-29 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers
KR101314579B1 (en) * 2011-04-07 2013-10-10 광주과학기술원 Paclitaxel- loaded polymeric nanoparticle and preparation thereof
JP2013053103A (en) * 2011-09-05 2013-03-21 Ltt Bio-Pharma Co Ltd Liver-accumulative nanoparticle having drug encapsulated therein
WO2013124867A1 (en) * 2012-02-21 2013-08-29 Amrita Vishwa Vidyapeetham University Polymer - polymer or polymer - protein core - shell nano medicine loaded with multiple drug molecules
HUE043998T2 (en) 2012-09-17 2019-09-30 Pfizer Process for preparing therapeutic nanoparticles
US10143700B2 (en) 2013-02-19 2018-12-04 Amrita Vishwa Vidyapeetham Nanoparticle formulations for delivering multiple therapeutic agents
PE20160930A1 (en) 2013-09-16 2016-09-03 Astrazeneca Ab THERAPEUTIC POLYMERIC NANOPARTICLES AND METHODS FOR THEIR PREPARATION AND USE.
SI3116547T1 (en) 2014-03-14 2019-08-30 Pfizer, Inc. Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
EP3242653A1 (en) 2015-01-05 2017-11-15 Boston Scientific Scimed Inc. Biodegradable drug eluting microsphere for the treatment of solid tumors
GB201505527D0 (en) 2015-03-31 2015-05-13 Jmedtech Pte Ltd Composition
US9814685B2 (en) 2015-06-04 2017-11-14 Crititech, Inc. Taxane particles and their use
US20170128424A1 (en) * 2015-11-11 2017-05-11 Qrono, Inc. Sustained release pharmaceutical compositions and methods of use
SG10201913409VA (en) 2016-04-04 2020-03-30 Crititech Inc Methods for solid tumor treatment
CN106075535B (en) * 2016-06-14 2019-04-02 武汉纺织大学 A kind of medical dressing and preparation method thereof
WO2018011040A1 (en) * 2016-07-13 2018-01-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Plga microparticles loaded with a fluoroquinolone for the treatment of respiratory diseases
WO2018067545A1 (en) * 2016-10-04 2018-04-12 University Of Florida Research Foundation, Inc. Chondroprotective nanoparticles for the treatment of osteoarthritis
CN107049984A (en) * 2017-03-14 2017-08-18 武汉理工大学 A kind of preparation method for carrying taxol polylactic-co-glycolic acid microballoon
KR102024273B1 (en) * 2017-03-27 2019-11-04 주식회사 피에프디 Device and method for drug action management
BR112019023948A2 (en) 2017-06-09 2020-06-09 Crititech Inc treatment of epithelial cysts by intracystic injection of antineoplastic particles
AU2018284247B2 (en) 2017-06-14 2020-04-30 Crititech Inc. Methods for treating lung disorders
CA3076919A1 (en) 2017-10-03 2019-04-11 Crititech, Inc. Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer
WO2019071245A1 (en) 2017-10-06 2019-04-11 Foundry Therapeutics, Inc. Implantable depots for controlled release of analgesics to treat postoperative pain associated with orthopedic surgery, and associated devices, systems, and methods
WO2019136188A1 (en) * 2018-01-05 2019-07-11 Crititech, Inc. Treatment of bladder cancer by intratumoral injection of taxane particles
WO2019136490A1 (en) 2018-01-08 2019-07-11 Foundry Therapeutics, Inc. Devices, systems, and methods for treating intraluminal cancer via controlled delivery of therapeutic agents
GB201800912D0 (en) * 2018-01-19 2018-03-07 Ucl Business Plc Compositions for the treatment of a disease of the urinary tract and treatment of a disease involving the intracellular delivery of the particle
US12458589B2 (en) 2018-05-12 2025-11-04 Foundry Therapeutics, Inc. Implantable polymer depots for the controlled release of therapeutic agents
US20190365698A1 (en) * 2018-05-31 2019-12-05 Crititech, Inc. Use of Antineoplastic Agents to Stimulate the Immune System for Treatment of Cancer
US12303619B2 (en) 2018-08-28 2025-05-20 Foundry Therapeutics, Inc. Polymer implants
WO2020072090A1 (en) * 2018-10-03 2020-04-09 Crititech, Inc. Use of antineoplastic agents to stimulate the immune system for production of tertiary lymphoid structures (tls)
EP3750524A1 (en) * 2019-06-13 2020-12-16 CAPNOMED GmbH Delayed and sustained delivery of anticancer drugs
EP3750523A1 (en) * 2019-06-13 2020-12-16 CAPNOMED GmbH Active substance delivery system
EP3791865A1 (en) * 2019-09-16 2021-03-17 CAPNOMED GmbH Active substance delivery system with delayed delivery
JP7743083B2 (en) * 2020-10-08 2025-09-24 学校法人関西医科大学 Evaluation marker reflecting the efficacy of a cancer therapeutic composition
US20240016774A1 (en) * 2020-10-14 2024-01-18 Foundry Therapeutics, Inc. Implantable depots for localized, sustained, controlled release of therapeutic agents to treat cancer and related conditions
US20240307220A1 (en) * 2021-03-05 2024-09-19 H. Lee Moffitt Cancer Center And Research Institute Inc. Combination Therapy to Treat Temperature Sensitive Mutant Tumors
CN115770224B (en) * 2023-01-17 2023-04-18 中国人民解放军总医院第一医学中心 Acrylic acid microsphere carrying paclitaxel medicine and preparation method thereof
CN118649148B (en) * 2024-05-30 2024-11-01 河南中医药大学第一附属医院 Astragalus polysaccharide composite nanoparticles and preparation method and application thereof
CN118948780B (en) * 2024-08-07 2025-07-15 山东序列生物科技有限公司 Roxivirine freeze-dried preparation and preparation method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
WO2000066085A1 (en) * 1999-04-29 2000-11-09 Macromed, Inc. A bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
WO2002049620A2 (en) * 2000-12-21 2002-06-27 Inhale Therapeutic Systems, Inc. Induced phase transition method for the production of microparticles containing hydrophobic active agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495579B1 (en) * 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US20020164374A1 (en) * 1997-10-29 2002-11-07 John Jackson Polymeric systems for drug delivery and uses thereof
JP2003524624A (en) * 1999-04-09 2003-08-19 ジェシー エル エス オウ Methods and compositions for enhancing delivery of therapeutic agents to tissues
US6444227B1 (en) * 1999-08-05 2002-09-03 Roche Vitamins Inc. Process for preparing fat soluble beadlets
WO2002087563A2 (en) * 2001-05-01 2002-11-07 Angiotech Pharmaceuticals Inc. Compositions comprising an anti-microtubule agent and a polypeptide or a polysaccharide and the use thereof for the preparation of a medicament for the treatment of inflammatory conditions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
WO2000066085A1 (en) * 1999-04-29 2000-11-09 Macromed, Inc. A bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
WO2002049620A2 (en) * 2000-12-21 2002-06-27 Inhale Therapeutic Systems, Inc. Induced phase transition method for the production of microparticles containing hydrophobic active agents

Non-Patent Citations (17)

* Cited by examiner, † Cited by third party
Title
AM. INST. CHEM. ENGINEERS, 3 November 2002 (2002-11-03) - 8 November 2002 (2002-11-08), pages 2113 - 2123 *
ANNALS ACAD. MED., vol. 29, no. 5, 2000, SINGAPORE, pages 633 - 639 *
DATABASE EMBASE [online] FENG S. ET AL.: "Nanospheres of biodegradable polymers: a system for clinical administration of an anticancer drug paclitaxel (taxol)", XP002985963, accession no. STN Database accession no. 2000401423 *
DATABASE EMBASE [online] FONSECA C. ET AL.: "Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity", XP002985962, accession no. STN Database accession no. 2002399915 *
DATABASE EMBASE [online] MENEI P. ET AL.: "Drug delivery into the brain using implantable polymeric systems", XP002985961, accession no. STN Database accession no. 1999139151 *
DATABASE EMBASE [online] MU L. ET AL.: "A novel controlled release formulation for the anticancer drug paclitaxel (taxol) : PLGA nanoparticles containing vitamin E TPGS", XP002985964, accession no. STN Database accession no. 2002457441 *
DATABASE EMBASE [online] NASTRUZZI I.C. ET AL.: "Production and in vitro evaluation of gelatin microspheres containing an antitumor tetra-amidine", XP002985966, accession no. STN Database accession no. 94158303 *
DATABASE EMBASE [online] SHENDEROVA A. ET AL.: "The acid microclimate in poly(lactide-co-glycolide)microspheres stabilizes camptothecins", XP002985965, accession no. STN Database accession no. 1999103623 *
DATABASE HCAPLUS [online] ALBAYRAK C.: "Induced phase transition method for the production of microparticles containing hydrophobic active agents", XP002985958, accession no. STN Database accession no. 137:681156 *
DATABASE HCAPLUS [online] FOO W. ET AL.: "Characterization of paclitaxel-loaded biodegradable particulate systems", XP002985959, accession no. STN Database accession no. 139:399612 *
DATABASE HCAPLUS [online] SHIH C. ET AL.: "Drug delivery system based on biodegradable polyester microparticles", XP002985960, accession no. STN Database accession no. 133:340262 *
J. CONTROLLED RELEASE, vol. 83, no. 2, 4 October 2002 (2002-10-04), pages 273 - 286 *
J. CONTROLLED RELEASE, vol. 86, no. 1, 9 January 2003 (2003-01-09), pages 33 - 48 *
J. MICROENCAPSULATION, vol. 11, no. 3, 1994, pages 249 - 260 *
PHARMACEUTICAL RESEARCH, vol. 16, no. 2, 1999, pages 241 - 243 *
S.T.P. PHARMA SCI., vol. 7, no. 1, 1997, pages 53 - 61 *
See also references of EP1608359A4 *

Also Published As

Publication number Publication date
CN102697737B (en) 2014-03-19
JP2006522148A (en) 2006-09-28
AU2009200463A1 (en) 2009-03-05
CN102697737A (en) 2012-10-03
KR100849911B1 (en) 2008-08-04
AU2004228008A1 (en) 2004-10-21
EP1608359A4 (en) 2011-08-17
JP4927535B2 (en) 2012-05-09
EP1608359A2 (en) 2005-12-28
CN1816331A (en) 2006-08-09
KR20060006911A (en) 2006-01-20
WO2004089291A2 (en) 2004-10-21
IL171185A (en) 2013-07-31
AU2004228008B2 (en) 2008-11-06
CN1816331B (en) 2012-08-08
CA2520475A1 (en) 2004-10-21
CA2520475C (en) 2012-10-09

Similar Documents

Publication Publication Date Title
WO2004089291A3 (en) Tumor-targeting drug-loaded particles
Bahadur et al. Current promising treatment strategy for glioblastoma multiform: A review
Frank et al. Improving drug biological effects by encapsulation into polymeric nanocapsules
Vishnubhakthula et al. Recent advances in hydrogel‐based drug delivery for melanoma cancer therapy: A mini review
Vellimana et al. Combination of paclitaxel thermal gel depot with temozolomide and radiotherapy significantly prolongs survival in an experimental rodent glioma model
Khaira et al. Development and characterization of nanoparticles for the delivery of gemcitabine hydrochloride
WO2005016262A3 (en) Methods for administering aripiprazole
Ghafari et al. Development of a novel liposomal nanoparticle formulation of cisplatin to breast cancer therapy
Tsai et al. Paclitaxel-loaded polymeric microparticles: quantitative relationships between in vitro drug release rate and in vivo pharmacodynamics
DE60237372D1 (en) MAGNETIC RETENTION SYSTEM WITH CONTROLLED MEDICINAL RELEASE
AR011133A1 (en) CONTROLLED RELEASE MICROGRANULES CONTAINING CISPLATINE, PROCEDURE FOR ITS PREPARATION, PHARMACEUTICAL COMPOSITION AND USE IN THE MANUFACTURE OF A POLYCHIMOTHERAPY MEDICATION OR IN ASSOCIATION WITH RADIOTHERAPY.
WO2004047768A3 (en) Buoyant polymer particles delivering therapeutic agents
Padmakumar et al. Intraperitoneal chemotherapy for ovarian cancer using sustained-release implantable devices
Sun et al. Hemostatic absorbable gelatin sponge loaded with 5-fluorouracil for treatment of tumors
WO2002085304A3 (en) Proliposomal drug delivery system
Tang et al. Enhanced efficacy of local etoposide delivery by poly (ether-anhydride) particles against small cell lung cancer in vivo
de Mendoza et al. Lipid nanosystems enhance the bioavailability and the therapeutic efficacy of FTY720 in acute myeloid leukemia
Alinezhad et al. Utilization of curcumine and nanocurcumine compounds in cancer therapy
Mao et al. Novel alginate–chitosan composite microspheres for implant delivery of vancomycin and in vivo evaluation
Blanco-Prıeto et al. In vitro evaluation of gentamicin released from microparticles
Mishra et al. Design of novel chemotherapeutic delivery systems for colon cancer therapy based on oral polymeric nanoparticles
Kukkar et al. Recent advances in nanoscale materials for antibody-based cancer theranostics
Choi et al. Inhibition of tumor growth by biodegradable microspheres containing all‐trans‐retinoic acid in a human head‐and‐neck cancer xenograft
Zembko et al. Development of disulfiram-loaded poly (lactic-co-glycolic acid) wafers for the localised treatment of glioblastoma multiforme: a comparison of manufacturing techniques
Xie et al. Intratumoral delivery of paclitaxel-loaded poly (lactic-co-glycolic acid) microspheres for Hep-2 laryngeal squamous cell carcinoma xenografts

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2520475

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 171185

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2006509638

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 11242546

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1020057018841

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2004758803

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2004228008

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2004228008

Country of ref document: AU

Date of ref document: 20040402

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004228008

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 20048156847

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2004758803

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020057018841

Country of ref document: KR